NCT02448771View on ClinicalTrials.gov

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 9, 2015

Primary Completion Date

August 12, 2019

Study Completion Date

March 3, 2021

Conditions
Breast Cancer Stage IVUnresectable Locally Advanced Invasive Breast CancerMetastatic Invasive Breast Cancer
Interventions
DRUG

Palbociclib

DRUG

Bazedoxifene

Trial Locations (2)

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02448771 - A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer | Biotech Hunter | Biotech Hunter